The Geron Corporation (NASDAQ:GERN) rally this month has moved one notch higher. The company shares have risen by a phenomenal 151% in this month alone. Analysts are of the opinion that the rally is not going to abate anytime soon. The purchase of the 3K, 3rd November calls had been partly-funded by the sale of the 3K, 5th November strike-calls. The upside of this particular trade is capped. However, if the company’s shares move beyond the $5.00 mark before expiration, investors can still rake in a tidy profit.
Friday’s trading stats
In Friday’s trading session, Geron Corporation (NASDAQ:GERN) rose by 10.45%. The shares opened at a price of $3.35 which climbed to an intraday high of $3.95 and dropped to a close of $3.70. Approximately 6.10 million shares were traded on Friday and the average volume of shares traded over 30 days was 1.63 million. The 52-week low of the shares is $0.91 and the 52-week high is $3.95. The company has a market capitalization of $476.00 million.
Geron Corporation (NASDAQ:GERN) was incorporated on 28 November 1990. It is a clinical stage bio-pharma company that is developing imetelstat, a 1st in class telomerase inhibitor that is used in the treatment of hematologic myeloid-malignancies.
The enzyme, Telomerase enables cancer-cells to maintain their telomere length. This provides them with the ability to replicate their sells limitlessly. Imetelstat is a specific-inhibitor of telomerase. Geron Corporation (NASDAQ:GERN) is focused on imetelstat development to be used in the treatment of hematologic myeloid malignancies such as myelofibrosis myelodysplastic syndromes or acute myelogenous leukemia.
The company’s revenue stream
Its revenues are generated from research-support payments under milestones and collaboration-agreements royalties as well as other revenues from its various licensing arrangements. Geron Corporation (NASDAQ:GERN) has one business segment, the discovery & development of therapeutic-products for